LUNG CANCER THERAPEUTICS MARKET ANALYSIS

Lung Cancer Therapeutics MarketSize and Trends

Rising incidences of non-small cell lung cancer is expected to drive the global lung cancer therapeutics market

According to the World Health Organization estimates in 2017, 1.8 million new lung cancer cases were diagnosed in 2012 globally accounting for the leading causes of morbidity and mortality. The launch of innovative radiation therapies, premium priced drugs, and rising incidences of non-small cell lung cancer (NSCLC) are the major driving factors for the growth of the market. The rising demand for targeted therapies is likely to have an optimistic impact over the lung cancer therapeutics market in the forecast period. Targeted therapies block the growth by targeting cancer-specific proteins, cells, and tissues that lead to cancer survival and division, without damaging the healthy cells. They are also proved to have higher efficiency over conventional therapies like platinum-based chemotherapy, surgical resection, and radiation therapy. Increasing diagnostic facilities by the Government, rise in unhealthy lifestyles, and increasing pollution due to rapid industrialization are the prominent factors driving the global lung cancer therapeutics market. The novel treatment termed targeted therapy is expected to have positive impact on the market